Atrium CSO awarded RSUs and 60,000 stock options

Atrium Therapeutics, Inc. Chief Scientific Officer Husam Younis reported equity compensation awards.

Rhea-AI Filing Summary

Atrium Therapeutics, Inc. Chief Scientific Officer Husam Younis reported equity compensation awards. He received 30,000 shares of common stock as restricted stock units, which vest 25% on March 20, 2027 and then in three yearly installments, contingent on continued service. He was also granted options for 60,000 shares of common stock at an exercise price of $14.30 per share, vesting 25% on March 20, 2027 and the balance in 36 equal monthly installments through April 20, 2036. Following the stock award, his direct common stock holdings total 52,657 shares.

Insider Trade Summary

Grant/Award: 90,000 shares

Grant/Award 2 txns

Insider Younis Husam

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	60,000	$0.00	$0.00
Grant/Award	Common Stock	30,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 60,000 contracts (Direct); Common Stock — 52,657 shares (Direct)

Footnotes (2)

1. F1. Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five percent (25%) of the RSUs shall vest on March 20, 2027, with the remaining RSUs vesting in three (3) substantially equal yearly installments each year thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
2. F2. Twenty-five percent (25%) of the shares underlying this option shall vest and become exercisable on March 20, 2027, with the remaining shares vesting in thirty-six (36) substantially equal monthly installments each month thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

Key Figures

RSU grant: 30,000 shares Option grant size: 60,000 shares Option exercise price: $14.30 per share +4 more

7 metrics

RSU grant 30,000 shares Restricted stock units awarded to CSO on April 20, 2026

Option grant size 60,000 shares Stock options for common stock granted on April 20, 2026

Option exercise price $14.30 per share Exercise price for 60,000 stock options

Common shares held after grant 52,657 shares Direct common stock holdings after RSU award

RSU initial vesting date March 20, 2027 25% of RSUs vest on this date

Option vesting pattern 25% then 36 monthly installments Vesting schedule after March 20, 2027

Option expiration April 20, 2036 Expiration date of the stock options

Key Terms

restricted stock units ("RSUs"), Stock Option (Right to Buy), vest, exercise price, +1 more

5 terms

restricted stock units ("RSUs") financial

"Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) with an exercise price of $14.30 per share"

vest financial

"Twenty-five percent (25%) of the RSUs shall vest on March 20, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

exercise price financial

"shares underlying this option shall vest and become exercisable with a $14.30 exercise price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

monthly installments financial

"remaining shares vesting in thirty-six (36) substantially equal monthly installments"

Monthly installments are regular, fixed payments made each month to gradually pay off a larger amount, such as a loan or purchase. Think of it like paying for a big item in small, manageable parts instead of all at once. For investors, understanding installment payments helps gauge how debts are structured and how they might affect financial stability or cash flow over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Atrium Therapeutics (RNA) disclose in this Form 4 for Husam Younis?

Atrium Therapeutics reported that Chief Scientific Officer Husam Younis received equity compensation, including restricted stock units and stock options. These grants increase his direct equity stake and are subject to multi‑year vesting tied to his continued service with the company.

How many Atrium Therapeutics (RNA) shares did Husam Younis receive as restricted stock units?

Husam Younis was granted 30,000 restricted stock units, each representing one share of Atrium’s common stock. Twenty‑five percent vest on March 20, 2027, with the remaining units vesting in three substantially equal yearly installments, conditioned on his continuous service.

What stock options were granted to Husam Younis by Atrium Therapeutics (RNA)?

He received stock options covering 60,000 shares of Atrium Therapeutics common stock. The options have a $14.30 exercise price, with 25% vesting on March 20, 2027 and the remainder vesting in 36 equal monthly installments, subject to continued service.

When do Husam Younis’s Atrium Therapeutics (RNA) RSUs and options vest?

Both awards start vesting on March 20, 2027. For RSUs, 25% vest then and the rest in three annual installments. For options, 25% vest on that date and the remaining shares vest monthly over 36 months, assuming ongoing employment.

What are Husam Younis’s Atrium Therapeutics (RNA) share holdings after this Form 4?

After the reported grant of restricted stock units, Husam Younis directly holds 52,657 shares of Atrium Therapeutics common stock. This figure reflects his position following the acquisition reported, separate from the newly granted but unexercised stock options.

What is the expiration date of Husam Younis’s Atrium Therapeutics (RNA) stock options?

The stock options granted to Husam Younis are scheduled to expire on April 20, 2036. They vest over time starting March 20, 2027, with 25% vesting initially and the remaining portion vesting in 36 equal monthly installments, assuming continuous service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/22/2026 - 05:40 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Younis Husam

(Last) (First) (Middle)

C/O ATRIUM THERAPEUTICS, INC.

10578 SCIENCE CENTER DRIVE, SUITE 125

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Atrium Therapeutics, Inc. [ RNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/20/2026		A		30,000(1)	A	$0	52,657	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$14.3	04/20/2026		A		60,000		(2)	04/20/2036	Common Stock	60,000	$0	60,000	D

Explanation of Responses:

1. Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five percent (25%) of the RSUs shall vest on March 20, 2027, with the remaining RSUs vesting in three (3) substantially equal yearly installments each year thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

2. Twenty-five percent (25%) of the shares underlying this option shall vest and become exercisable on March 20, 2027, with the remaining shares vesting in thirty-six (36) substantially equal monthly installments each month thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

	/s/ Brendan Winslow, Attorney-in-Fact	04/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)